Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
I found this on MSN:

IBC Pharmaceuticals Begins Phase I/II Clinical Trial Of Pentacea(TM) in Cancer Therapy


March 1, 2000 07:31 AM
MORRIS PLAINS, N.J., March 1 /PRNewswire/ -- IBC Pharmaceuticals, LLC, a joint venture between Immunomedics, Inc. IMMU and Beckman Coulter Corporation BEC today announced the start of Phase I/II clinical trials of its lead product, Pentacea(TM), for the treatment of solid tumors. The clinical trial is currently open at two sites in France.
According to IBC Pharmaceuticals' Executive Vice President, Dr. John Reno: "Pentacea delivers cytotoxic radiation directly to patient's tumors that express carcinoembryonic antigen (CEA). CEA is expressed on most major solid tumors including those of the breast, colon, and lung. Pentacea is the first commercial drug to be developed using the Company's platform technology based on 2-step pretargeting. In the first step, a bispecific antibody is given to the patient. One part of the bispecific antibody targets the patient's tumor and the other part will bind to the subsequently administered radioactive small molecule. Upon administration, the radioactive small molecule binds to the bispecific antibody at the tumor. Any unbound radioactivity is rapidly eliminated from the body through the kidneys. Using this technology, the toxicity normally observed with directly radiolabeled antibodies should be reduced thus permitting larger doses of radiation to be administered with improved therapeutic potential."

According to Professor Jean-Francois Chatal, M.D., National Medical Research Institute, Nantes, France, and lead clinical investigator, "Although we are still early in the clinical trial, Pentacea has been well-tolerated in the patients who have received it. We had previously studied an early version of the drug in a clinical trial in patients with small cell lung cancer and achieved objective clinical responses in 3 patients out of 12 studied, with a clear indication of increased survival. We are excited to be studying this new, improved drug."

IBC Pharmaceuticals is developing radiopharmaceutical products for the treatment of cancer based on its proprietary pretargeting technology. Its lead product, Pentacea(TM), is in Phase I/II clinical trials for the treatment of small cell lung cancer.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty. Although IBC Pharmaceuticals, LLC (the "Company") believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate.

Important factors that could cause actual results to differ materially from the forward-looking statements include the Company's need to obtain substantial additional capital (through financings or otherwise) to fund its operations and the progress of development, testing, and licensing/commercialization of the Company's technologies. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

SOURCE IBC Pharmaceuticals, LLC


DB



Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.